• Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

      Lindsay, Colin R.; email: colin.lindsay@manchester.ac.uk; Shaw, Emily C.; Moore, David A.; Rassl, Doris; Jamal-Hanjani, Mariam; Steele, Nicola; Naheed, Salma; Dick, Craig; Taylor, Fiona; Adderley, Helen; et al. (Nature Publishing Group UK, 2021-09-06)
      Abstract: Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
    • Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.

      Lindsay, Colin R; email: colin.lindsay@manchester.ac.uk; Shaw, Emily C; Moore, David A; Rassl, Doris; Jamal-Hanjani, Mariam; Steele, Nicola; Naheed, Salma; Dick, Craig; Taylor, Fiona; Adderley, Helen; et al. (2021-09-06)
      Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies. [Abstract copyright: © 2021. The Author(s).]